KURA: Kura Oncology, Inc.
Performance
KURA -23.23%
Watchlist
Select an item
Summary
KURA at a glance
KURA returned -23.23% over the past year and -17.26% a year over five years. Its worst drop in that year was -49.96%, smaller than 23% of stocks on Redstone, and its Sharpe ratio of -0.16 beats 20% of stocks on Redstone. It pays no dividends.
Current Drawdown
-44.30%
Rolling Volatility
104.94%
Actions
Metrics
Risk Indicators
Alpha-23.39%
Beta1.34x
Sharpe-0.16
Sortino-0.22
Omega0.97
Calmar-0.46
Martin-0.45
Profile
About KURA
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $673M
- Listed
- Aug 2015
- Employees
- 260
- Headquarters
- San Diego, CA
- Website
- kuraoncology.com
Comparisons